Comparative Study to Evaluate Role of Amoxclav and Levofloxacin in Managing Acute Sinusitis: An Institutional Based Study

Abstract

Background: Acute rhinosinusitis is defined pathologically by transient inflammation of the mucosal lining of the paranasal sinuses lasting less than 4 weeks. A vast majority of patients have the tendency to recover without the use of antibiotics but in patients with prolonged or severe disease, the use of antibiotics should be given consideration. The present study was conducted to compare the amoxclav and levofloxacin in managing acute sinusitis.Materials and Methods: The present prospective study was conducted to compare the amoxclav and levofloxacin in managing acute sinusitis. The patients were divided into two groups, in Group I patient’s amoxicillin-clavulanate was given and in Group II levofloxacin was given. Patient’s complete demographic details were recorded. Assessment of all the patients was done and data was collected. The recorded data was compiled, and data analysis was done using SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). P-value less than 0.05 was considered statistically significant.Results: In the present study, a total of 240 subjects were enrolled, 120 subjects belonged to Group I in which amoxclav was given and in patients of Group II, levofloxacin was given. In both the groups, majority of the subjects were between 40-50 years of age. There were 40.83% in Group I and 45.83% in Group II who belonged to this age group. The clinical outcome of the therapy showed that there were 53.33% cases in Group I and 49.16% cases in Group II who were completely cured. 28.33% Improved cases were seen in Group I and 25.83% cases of Group II. No improvement was seen in 18.33% cases of Group I and 25% cases of Group II.Conclusion: The present study concluded that Amoxclav completely more cases than levofloxacin. Improved cases were also more with amoxclav. Failed cases were more with levofloxacin. this shows that clinical outcome with amoxclav was better than levofloxacin.